Integrated Summaries Case Study

Case Study Introduction

This case study considers the production of an ISS and ISE for an orphan drug. The fact that the compound was an orphan drug introduced some unique problems, as the number of patients was lower than in most integrated summaries.

Due to close collaboration between the clinical team and the statistician, identification of all these issues occurred during the writing of the statistical analysis plans. This enabled identification and explanation of the appropriate methods prior to starting the analyses.

Objectives and Key Challenges

The primary endpoint was time to beginning of relief of symptom. However, in one pivotal study the definition used the time of first identification of relief of symptoms, whilst in the second study persistence of the symptoms was also required.

The drug was developed to treat patients who had an underlying genetic disease that resulted in frequent attacks. Studies included healthy volunteers, asymptomatic patients and patients suffering from an attack. Trials that included healthy volunteers and asymptomatic patients were primarily uncontrolled. However, including patients from these trials in the ISS had the potential to bias the denominator when assessing the group of patients at risk.

Due to the excellent efficacy and difficulty in recruiting high patient numbers, the number of patients treated in a Randomized Controlled Trial (RCT) was very low (N = 38 treated with the marketed drug, of which only 12 had been treated at the recommended marketing dose).

Patients suffered multiple attacks, and sometimes received multiple treatments in the open-label extension phases. The regulatory authorities raised concerns that the efficacy of the drug may reduce when taken multiple times.

The regulatory authorities raised similar concerns over the safety impact of treating patients multiple times.

Prior to treatment, the severity of the patient’s attack was assessed to decide whether the subject was eligible. However, the criteria for assessing the attack’s eligibility were different in the early studies compared to the pivotal studies. In addition, the primary endpoint used a VAS that assessed severity of symptoms, but the VAS in the early phase studies assessed the change in severity of symptoms since baseline.

Receipt of certain doses only occurred in a single trial. If trial was included as a covariate in the analyses this was confounded with treatment, meaning that the treatment effect could not be accurately estimated.

There were a large number of different treatment regimens, so presenting by regimen made producing combined results difficult.

Need to manage complex integrated summaries under tight deadlines?

See how our specialists can help you streamline data integration, strengthen analysis, and support a smoother submission path. Contact us today.

Speak to our data experts

Strategic Approach and Tailored Solutions

The primary analysis for the ISE was defined as time to beginning of relief of symptoms with persistence to avoid any potential for multiple primary endpoints in the ISE.

Two separate sets of safety summaries were produced from a single derived database. One set for symptomatic patients and the other set for asymptomatic patients and healthy volunteers.

After discussions with the regulatory authorities, results from the open-label extensions were also included in the ISE and ISS. The RCT trials were used to produce the key outputs discussed but use was made of supporting evidence from outputs incorporating the RCT and open-label information.

Statistical methodologies were employed that allowed within patient comparisons of the time to event primary endpoint. In addition, patients treated for more than 5 attacks were summarized using by patient figures to show that the efficacy did not decrease with multiple attacks.

AEs and other safety endpoints were summarized by attack. These were used in conjunction with immunological results, to show that there was no evidence of effects due to multiple dosing.

Based on the substantial differences in the early studies, and as these studies were not randomized controlled studies, they were included in the safety database but not the efficacy database.

For each analysis, careful consideration and adjustment of the covariates allowed the answering of the specific questions the analysis was trying to address.

Treatment doses were grouped into ‘Very low doses’ (known to be inefficacious), ‘Low doses’, ‘Marketing dose’ or ‘Higher than the marketing dose’. As well as allowing sensible grouping of treatment groups, this approach helped in justifying the choice of the requested marketing dose by showing that efficacy did not increase in higher doses. The safety of the dose was also justified by showing that safety in the higher dose was comparable to lower doses and placebo.

Optimised Timelines

The below example timelines are designed to show how front loading the planning and production of the ISS and ISE can enable the production of the outputs to be significantly reduced post unblinding of the pivotal studies. The timelines cover up until the production of final outputs but clearly the reduction in timelines to this stage enables a reduction to the final submission.

Some points to highlight in this plan:

Planning activities are in purple, production and validation pre-lock activities are in blue, and post-lock activities are in green.
There is significant time allowed for the planning stages (SAP, derived datasets) due to starting the process early. This careful planning reduces future timelines and the necessity for re-work.
Starting early enables the building of flexibility into the timelines. Therefore, if the pre database lock
timelines over run this will not affect the final submission.
Multiple reviews prior to database lock of the pivotal studies enable early finalization of the formatting of the outputs. Therefore, the review after the database lock can concentrate purely on the results.
These review runs also allow a thorough check of the combining of data from the earlier studies.
Taking a data cut shortly before database lock of the pivotal studies enables validation of the integrated database on near final data, reducing the timelines post-lock.
Although timelines post database lock of the pivotal studies are significantly reduced, time is still allowed between the results review meeting and finalization of outputs to address specific questions arising from the results of the pivotal studies.

Conclusion

By combining early strategic planning with close collaboration between the clinical and statistical teams, Quanticate helped the sponsor navigate the unique complexities of preparing integrated summaries for an orphan drug with limited patient numbers, varied study designs, and repeated treatment exposure.

Through careful methodological decisions, robust data integration, and proactive engagement with regulatory expectations, the team was able to generate clear, credible ISS and ISE outputs that supported both efficacy and safety evaluation.

This approach not only addressed the challenges of a rare disease development programme, but also demonstrated how front-loaded planning can reduce post-lock timelines, minimise rework, and strengthen the overall submission strategy.

Integrated Summaries of Safety (ISS) and Efficacy (ISE) for an Orphan Drug